Andrew T. Braun

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Claire Keating, Lael M. Yonker, F. Vermeulen et al. · The Lancet Respiratory Medicine · 2025 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls

Paolo Biselli, Kathrin Fricke, Ludger Grote et al. · European Respiratory Journal · 2018 · 74 citations · Full text

Medicine, Physiology, Pulmonology +16

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor

Mark T. Jennings, Rebecca Dezube, Shruti Paranjape et al. · Annals of the American Thoracic Society · 2017 · 66 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Ahmet Uluer, Gordon MacGregor, Pilar Azevedo et al. · The Lancet Respiratory Medicine · 2023 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9